
Ocupres0.5%
Popular Pharmaceuticals Ltd.
Timolol Maleate is a non-selective beta-adrenergic blocking agent used both topically (as eye drops) and, in some markets, orally (as tablets), depending on the indication.
Timolol Maleate is a non-selective beta-adrenergic blocking agent used both topically (as eye drops) and, in some markets, orally (as tablets), depending on the indication.
In Bangladesh, Timolol Maleate is primarily marketed and used as an ophthalmic (eye drop) preparation for glaucoma and ocular hypertension.
| Formulation | Typical adult dose |
|---|---|
| Timolol Maleate ophthalmic solution 0.25% or 0.5% | 1 drop in the affected eye(s) twice daily; if controlled, may reduce to once daily |
| Timolol Maleate gel-forming ophthalmic solution 0.25% or 0.5% | 1 drop in the affected eye(s) once daily in the morning |
If switching from another ophthalmic beta-blocker, discontinue that medicine and begin Timolol Maleate the following day. Intraocular pressure should be re-checked after about 4 weeks of use, as the ocular hypotensive effect may stabilize after this period.
| Indication | Typical adult dose |
|---|---|
| Hypertension | Initially 10 mg twice daily, increased gradually at intervals of at least 7 days to a usual maintenance dose of 20-40 mg daily in divided doses (maximum per label up to 60 mg/day) |
| Post-myocardial infarction | 10 mg twice daily in clinically stable patients, usually starting within 1-4 weeks after infarction |
| Migraine prophylaxis | 10 mg twice daily initially; usual maintenance range 10-30 mg daily |
Oral Timolol Maleate must not be stopped abruptly; the dose should be tapered gradually over 1-2 weeks under medical supervision (see Precautions and Warnings).
Administration technique and timing are detailed under Administration below.
Patients should seek prompt medical attention for signs of a very slow heart rate, fainting, severe shortness of breath, or wheeze while using Timolol Maleate.
Timolol Maleate is contraindicated in patients with:
These contraindications apply to both ophthalmic and oral forms of Timolol Maleate, because clinically significant systemic beta-blockade can occur even after topical (eye drop) administration due to systemic absorption.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.